Does RIBOCICLIB Cause Breast cancer recurrent? 180 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 180 reports of Breast cancer recurrent have been filed in association with RIBOCICLIB (KISQALI). This represents 0.6% of all adverse event reports for RIBOCICLIB.
180
Reports of Breast cancer recurrent with RIBOCICLIB
0.6%
of all RIBOCICLIB reports
21
Deaths
64
Hospitalizations
How Dangerous Is Breast cancer recurrent From RIBOCICLIB?
Of the 180 reports, 21 (11.7%) resulted in death, 64 (35.6%) required hospitalization, and 18 (10.0%) were considered life-threatening.
Is Breast cancer recurrent Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RIBOCICLIB. However, 180 reports have been filed with the FAERS database.
What Other Side Effects Does RIBOCICLIB Cause?
Neutropenia (3,585)
Nausea (3,404)
Fatigue (3,327)
Malignant neoplasm progression (2,468)
Death (2,452)
Vomiting (1,953)
Diarrhoea (1,830)
White blood cell count decreased (1,683)
Pain (1,637)
Metastases to bone (1,538)
What Other Drugs Cause Breast cancer recurrent?
LETROZOLE (285)
TRASTUZUMAB (268)
TAMOXIFEN (260)
FULVESTRANT (219)
ANASTROZOLE (214)
CYCLOPHOSPHAMIDE (182)
PACLITAXEL (151)
DOCETAXEL (138)
PALBOCICLIB (126)
DOXORUBICIN (114)
Which RIBOCICLIB Alternatives Have Lower Breast cancer recurrent Risk?
RIBOCICLIB vs RIBOFLAVIN
RIBOCICLIB vs RIBOFLAVIN 5'-PHOSPHATE
RIBOCICLIB vs RIBOFLAVIN 5^-PHOSPHATE
RIBOCICLIB vs RIFABUTIN
RIBOCICLIB vs RIFAMPICIN